HBM HOLDINGS-B (02142) jumped over 8% in early trading. As of press time, the stock was up 6.3% to HK$16.36, with trading volume reaching HK$58.26 million.

On the news front, the Nobel Prize in Physiology or Medicine was recently announced, with Mary E. Brennan, Fred Ramsdell, and Shimon Sakaguchi receiving the award for their groundbreaking work in "peripheral immune tolerance." Analysts note that this Nobel Prize announcement is expected to ignite enthusiasm for Treg cell therapy technology and innovative drug development.

HBM Holdings has developed HBM4003, a next-generation antibody targeting the CTLA-4 pathway, which has demonstrated excellent safety characteristics in clinical studies. The company has observed clear efficacy signals across multiple tumor types including colorectal cancer, liver cancer, and neuroendocrine tumors, potentially unlocking the full therapeutic value of the CTLA-4 target.

In another core target area, CCR8, HBM Holdings has developed the HBM1022 antibody targeting this pathway. This antibody has emerged as a highly promising "seed candidate" in the company's pipeline and is expected to bring new breakthroughs to cancer immunotherapy.